Novartis AG is the latest big pharma to exit the antibiotics arena, deciding to ditch its antibacterial and antiviral research programs and spend its resources in other areas.
The Swiss major confirmed the decision in an email to Scrip saying that workers at its Emeryville, California facilities have...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
